메뉴 건너뛰기




Volumn 29, Issue 7, 2009, Pages 800-811

Statin-associated adverse cognitive effects: Survey results from 171 patients

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitor; ADR; Adverse drug reaction; Cholesterol; Cognition; HMG CoA reductase inhibitor; Memory; Statin

Indexed keywords

ATORVASTATIN; CERIVASTATIN; EZETIMIBE; FLUINDOSTATIN; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

EID: 67650805429     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.7.800     Document Type: Article
Times cited : (156)

References (84)
  • 3
    • 12444320258 scopus 로고    scopus 로고
    • Coxibs, science, and the public trust
    • Solomon DH, Avorn J. Coxibs, science, and the public trust. Arch Intern Med 2005;165:158-160
    • (2005) Arch Intern Med , vol.165 , pp. 158-160
    • Solomon, D.H.1    Avorn, J.2
  • 4
    • 0037190089 scopus 로고    scopus 로고
    • Postmarketing surveillance and black box warnings
    • Graham GK. Postmarketing surveillance and black box warnings. JAMA 2002;288:955-959
    • (2002) JAMA , vol.288 , pp. 955-959
    • Graham, G.K.1
  • 5
    • 0033559723 scopus 로고    scopus 로고
    • Postmarketing surveillance: Strengths and limitations. the flucloxacillin-dicloxacillin story
    • McNeil JJ, Grabsch EA, McDonald MM. Postmarketing surveillance: strengths and limitations-the flucloxacillindicloxacillin story. Med J Aust 1999;170:270-273 (Pubitemid 29129345)
    • (1999) Medical Journal of Australia , vol.170 , Issue.6 , pp. 270-273
    • McNeil, J.J.1    Grabsch, E.A.2    McDonald, M.M.3
  • 6
  • 7
    • 0031280318 scopus 로고    scopus 로고
    • Monitoring for adverse drug events
    • Kennedy DL, Goldman SA. Monitoring for adverse drug events. Am Fam Physician 1997;56:1718-1721
    • (1997) Am Fam Physician , vol.56 , pp. 1718-1721
    • Kennedy, D.L.1    Goldman, S.A.2
  • 8
    • 0037236850 scopus 로고    scopus 로고
    • Consumer adverse drug reaction reporting: A new step in pharmacovigilance?
    • van Grootheest K, de Graaf L, de Jong-van den Berg LT. Consumer adverse drug reaction reporting: a new step in pharmacovigilance? Drug Saf 2003;26:211-217
    • (2003) Drug Saf , vol.26 , pp. 211-217
    • Van Grootheest, K.1    De Graaf, L.2    De Jong-van Den Berg, L.T.3
  • 9
    • 34548058076 scopus 로고    scopus 로고
    • Physician response to patient reports of adverse drug effects: Implications for patient-targeted adverse effect surveillance
    • DOI 10.2165/00002018-200730080-00003
    • Golomb BA, McGraw JJ, Evans MA, Dimsdale JE. Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance. Drug Saf 2007;30:669-675 (Pubitemid 47295826)
    • (2007) Drug Safety , vol.30 , Issue.8 , pp. 669-675
    • Golomb, B.A.1    McGraw, J.J.2    Evans, M.A.3    Dimsdale, J.E.4
  • 10
    • 0345689707 scopus 로고    scopus 로고
    • A comparison of adverse drug reaction reports from professionals and users, relating to risk of dependence and suicidal behaviour with paroxetine
    • Medawar C, Herxheimer A. A comparison of adverse drug reaction reports from professionals and users, relating to risk of dependence and suicidal behavior. Int J Risk Safety Med 2003-2004;16:5-19 (Pubitemid 37475764)
    • (2003) International Journal of Risk and Safety in Medicine , vol.16 , Issue.1 , pp. 5-19
    • Medawar, C.1    Herxheimer, A.2
  • 11
    • 0035372490 scopus 로고    scopus 로고
    • Summary of the third report of the national cholesterol education program adult treatment panel III
    • Lepor NE, Vogel RE. Summary of the third report of the national cholesterol education program adult treatment panel III. Rev Cardiovasc Med 2001;2:160-165
    • (2001) Rev Cardiovasc Med , vol.2 , pp. 160-165
    • Lepor, N.E.1    Vogel, R.E.2
  • 12
    • 8844246477 scopus 로고    scopus 로고
    • Implications of recent clinical trials for the national cholesterol education program ault treatment panel III guidelines
    • Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the national cholesterol education program ault treatment panel III guidelines. Arterioscler Thromb Vasc Biol 2004;24:e149-61
    • (2004) Arterioscler Thromb Vasc Biol , vol.24
    • Grundy, S.M.1    Cleeman, J.I.2    Merz, C.N.3
  • 15
    • 0036787034 scopus 로고    scopus 로고
    • Statin-associated myopathy with normal creatine kinase levels
    • Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002;137:581-585
    • (2002) Ann Intern Med , vol.137 , pp. 581-585
    • Phillips, P.S.1    Haas, R.H.2    Bannykh, S.3
  • 17
    • 20444469339 scopus 로고    scopus 로고
    • How common is rhabdomyolysis in patients receiving lipid-lowering therapy?
    • Phillips PS. How common is rhabdomyolysis in patients receiving lipid-lowering therapy? Nat Clin Pract Cardiovasc Med 2005;2:130-131
    • (2005) Nat Clin Pract Cardiovasc Med , vol.2 , pp. 130-131
    • Phillips, P.S.1
  • 19
    • 33847243361 scopus 로고    scopus 로고
    • Systematic review and meta-analysis of clinically relevant adverse events from HMG-CoA reductase inhibitor trials worldwide from 1982 to present
    • McClure DL, Valuck RJ, Glanz M, Hokanson JE. Systematic review and meta-analysis of clinically relevant adverse events from HMG-CoA reductase inhibitor trials worldwide from 1982 to present. Pharmacoepidemiol Drug Saf 2007;16:132-143
    • (2007) Pharmacoepidemiol Drug Saf , vol.16 , pp. 132-143
    • McClure, D.L.1    Valuck, R.J.2    Glanz, M.3    Hokanson, J.E.4
  • 21
    • 33746742345 scopus 로고    scopus 로고
    • Short-term memory loss associated with rosuvastatin
    • DOI 10.1592/phco.26.8.1190
    • Galatti L, Polimeni G, Salvo F, Romani M, Sessa A, Spina E. Short-term memory loss associated with rosuvastatin. Pharmacotherapy 2006;26:1190-1192 (Pubitemid 44167829)
    • (2006) Pharmacotherapy , vol.26 , Issue.8 I , pp. 1190-1192
    • Galatti, L.1    Polimeni, G.2    Salvo, F.3    Romani, M.4    Sessa, A.5    Spina, E.6
  • 22
    • 33947247905 scopus 로고    scopus 로고
    • Psychiatric adverse reactions with statins, fibrates and ezetimibe: Implications for the use of lipid-lowering agents
    • Tatley M, Savage R. Psychiatric adverse reactions with statins, fibrates and ezetimibe: implications for the use of lipidlowering agents. Drug Saf 2007;30:195-201 (Pubitemid 46425633)
    • (2007) Drug Safety , vol.30 , Issue.3 , pp. 195-201
    • Tatley, M.1    Savage, R.2
  • 24
  • 26
    • 0038381775 scopus 로고    scopus 로고
    • Statin-associated memory loss: Analysis of 60 case reports and review of the literature
    • DOI 10.1592/phco.23.7.871.32720
    • Wagstaff LR, Mitton MW, McLendon Arvik B, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003;23:871-880 (Pubitemid 36875671)
    • (2003) Pharmacotherapy , vol.23 , Issue.7 , pp. 871-880
    • Wagstaff, L.R.1    Mitton, M.W.2    Arvik, B.M.3    Doraiswamy, P.M.4
  • 28
    • 3843148550 scopus 로고    scopus 로고
    • Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults
    • DOI 10.1016/j.amjmed.2004.07.041, PII S0002934304005467
    • Muldoon MF, Ryan CM, Sereika SM, Flory JD, Manuck SB. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med 2004;117:823-829 (Pubitemid 39602790)
    • (2004) American Journal of Medicine , vol.117 , Issue.11 , pp. 823-829
    • Muldoon, M.F.1    Ryan, C.M.2    Sereika, S.M.3    Flory, J.D.4    Manuck, S.B.5
  • 29
    • 4444364340 scopus 로고    scopus 로고
    • Low and lowered cholesterol and total mortality
    • DOI 10.1016/j.jacc.2004.06.022, PII S0735109704012148
    • Criqui MH, Golomb BA. Low and lowered cholesterol and total mortality. J Am Coll Cardiol 2004;44:1009-1010 (Pubitemid 39165134)
    • (2004) Journal of the American College of Cardiology , vol.44 , Issue.5 , pp. 1009-1010
    • Criqui, M.H.1    Golomb, B.A.2
  • 30
    • 0019799332 scopus 로고
    • A method for estimating the probability of adverse drug reactions
    • Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245
    • (1981) Clin Pharmacol Ther , vol.30 , pp. 239-245
    • Naranjo, C.A.1    Busto, U.2    Sellers, E.M.3
  • 32
    • 0027987849 scopus 로고
    • Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
    • Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-1389 (Pubitemid 24365311)
    • (1994) Lancet , vol.344 , Issue.8934 , pp. 1383-1389
    • Pedersen, T.R.1
  • 33
    • 0032487931 scopus 로고    scopus 로고
    • Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
    • The Long-Term Intervention with Pravastatin in Ischaemic Disease (Lipid) Study Group. [see comments]
    • The Long-Term Intervention with Pravastatin in Ischaemic Disease (Lipid) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels [see comments]. N Engl J Med 1998;339:1349-1357
    • (1998) N Engl J Med , vol.339 , pp. 1349-1357
  • 36
    • 33847057676 scopus 로고    scopus 로고
    • Transient global amnesia in the district general hospital
    • DOI 10.1111/j.1742-1241.2006.00897.x
    • Larner AJ. Transient global amnesia in the district general hospital. Int J Clin Pract 2007;61:255-258 (Pubitemid 46271287)
    • (2007) International Journal of Clinical Practice , vol.61 , Issue.2 , pp. 255-258
    • Larner, A.J.1
  • 37
    • 43749105584 scopus 로고    scopus 로고
    • Transient global amnesia: A review
    • Shekhar R. Transient global amnesia: a review. Int J Clin Pract 2008;62:939-942
    • (2008) Int J Clin Pract , vol.62 , pp. 939-942
    • Shekhar, R.1
  • 38
    • 41049100570 scopus 로고    scopus 로고
    • update February Available from Accessed April 17, 2009
    • IMS Health. Commonly requested therapeutic class and product information (update February 2006). Available from http://www1.imshealth.com/ims/portal/ front/articleC/0,2777,65 99-18731-77056778,00.html. Accessed April 17, 2009
    • (2006) Commonly Requested Therapeutic Class and Product Information
  • 40
    • 67650848354 scopus 로고    scopus 로고
    • Available from Accessed May 23, 2005
    • IMS Health. Lipitor leads the way in 2003. Available from http://www.ims-global.com/insight/news-story /0403/news- story-040316.htm. Accessed May 23, 2005
    • Lipitor Leads the Way in 2003
  • 41
    • 67650787324 scopus 로고    scopus 로고
    • Available from Accessed May 2, 2008
    • IMS Health. IMS global insights-IMS retail drug Monitor December 2007. Available from http://www.imshealth.com /web/content/0,3148,64576068-63872702- 70260998-8374658 5,00.html. Accessed May 2, 2008
    • IMS Global Insights-IMS Retail Drug Monitor December 2007
  • 42
    • 0030972796 scopus 로고    scopus 로고
    • The rule of 5 and the rule of 7 in lipid-lowering by statin drugs
    • Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 1997;80:106-107
    • (1997) Am J Cardiol , vol.80 , pp. 106-107
    • Roberts, W.C.1
  • 43
    • 42949138132 scopus 로고    scopus 로고
    • Switching statin therapy using a pharmacist-managed therapeutic conversion program versus usual care conversion among indigent patients
    • DOI 10.1592/phco.28.5.553
    • Miller AE, Hansen LB, Saseen JJ. Switching statin therapy using a pharmacist-managed therapeutic conversion program versus usual care conversion among indigent patients. Pharmacotherapy 2008;28:553-561 (Pubitemid 351620023)
    • (2008) Pharmacotherapy , vol.28 , Issue.5 PART 1 , pp. 553-561
    • Miller, A.E.1    Hansen, L.B.2    Saseen, J.J.3
  • 45
    • 0032842577 scopus 로고    scopus 로고
    • Efficacy and safety of cerivastatin, 0.2 mg and 0.4 mg, in patients with primary hypercholesterolaemia: A multinational, randomised, double-blind study
    • Ose L, Luurila O, Eriksson J, Olsson A, Lithell H, Widgren B, for the Cerivastatin Study Group. Efficacy and safety of cerivastatin, 0.2 mg and 0.4 mg, in patients with primary hypercholesterolaemia: a multinational, randomised, doubleblind study. Curr Med Res Opin 1999;15:228-240 (Pubitemid 29481481)
    • (1999) Current Medical Research and Opinion , vol.15 , Issue.3 , pp. 228-240
    • Ose, L.1    Luurila, O.2    Eriksson, J.3    Olsson, A.4    Lithell, H.5    Widgren, B.6
  • 47
    • 42449117901 scopus 로고    scopus 로고
    • Reduction in blood pressure with statins: Results from the UCSD statin study, a randomized trial
    • DOI 10.1001/archinte.168.7.721
    • Golomb BA, Dimsdale JE, White HL, Ritchie JB, Criqui MH. Reductions in blood pressure with statins: results from the UCSD statin study, a randomized trial. Arch Intern Med 2008;168:721-727 (Pubitemid 351563955)
    • (2008) Archives of Internal Medicine , vol.168 , Issue.7 , pp. 721-727
    • Golomb, B.A.1    Dimsdale, J.E.2    White, H.L.3    Ritchie, J.B.4    Criqui, M.H.5
  • 48
    • 59549089180 scopus 로고    scopus 로고
    • Statin adverse effects: A review of the literature and evidence for a mitochondrial mechanism
    • Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008;8:373-418
    • (2008) Am J Cardiovasc Drugs , vol.8 , pp. 373-418
    • Golomb, B.A.1    Evans, M.A.2
  • 49
    • 49949104757 scopus 로고    scopus 로고
    • SLCO1B1 variants and statin-induced myopathy: A genomewide study
    • for The SEARCH Collaborative Group
    • Link E, Parish S, Armitage J, et al, for The SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy: a genomewide study. N Engl J Med 2008;359:789-799
    • (2008) N Engl J Med , vol.359 , pp. 789-799
    • Link, E.1    Parish, S.2    Armitage, J.3
  • 50
    • 0032572086 scopus 로고    scopus 로고
    • Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TEXCAPS, the Air Force/Texas coronary atherosclerosis prevention study
    • see comments
    • Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TEXCAPS, the Air Force/Texas coronary atherosclerosis prevention study [see comments]. JAMA 1998;279:1615-1622
    • (1998) JAMA , vol.279 , pp. 1615-1622
    • Downs, J.R.1    Clearfield, M.2    Weis, S.3
  • 51
    • 0032487931 scopus 로고    scopus 로고
    • Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
    • The Long-Term Intervention with Pravastatin in Ischaemic Disease (Lipid) Study Group
    • The Long-Term Intervention with Pravastatin in Ischaemic Disease (Lipid) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357
    • (1998) N Engl J Med , vol.339 , pp. 1349-1357
  • 53
    • 0942265627 scopus 로고    scopus 로고
    • Conceptual Foundations of the UCSD Statin Study: A Randomized Controlled Trial Assessing the Impact of Statins on Cognition, Behavior, and Biochemistry
    • DOI 10.1001/archinte.164.2.153
    • Golomb BA, Criqui MH, White H, Dimsdale JE. Conceptual foundations of the UCSD statin study: a randomized controlled trial assessing the impact of statins on cognition, behavior, and biochemistry. Arch Intern Med 2004;164:153-162 (Pubitemid 38140401)
    • (2004) Archives of Internal Medicine , vol.164 , Issue.2 , pp. 153-162
    • Golomb, B.A.1    Criqui, M.H.2    White, H.3    Dimsdale, J.E.4
  • 54
    • 1542381000 scopus 로고    scopus 로고
    • The UCSD Statin Study: A randomized controlled trial assessing the impact of statins on selected noncardiac outcomes
    • DOI 10.1016/j.cct.2003.08.014, PII S0197245603001806
    • Golomb BA, Criqui MH, White HL, Dimsdale JE. The UCSD statin study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomes. Control Clin Trials 2004;25:178-202 (Pubitemid 38328758)
    • (2004) Controlled Clinical Trials , vol.25 , Issue.2 , pp. 178-202
    • Golomb, B.A.1    Criqui, M.H.2    White, H.L.3    Dimsdale, J.E.4
  • 57
    • 0023267038 scopus 로고
    • Clinical Improvement after administration of coenzyme Q10 in a patient with mitochondrial encephalomyopathy
    • Goda S, Hamada T, Ishimoto S, Kobayashi T, Goto I, Kuroiwa Y. Clinical Improvement after administration of coenzyme Q10 in a patient with mitochondrial encephalomyopathy. J Neurol 1987;234:62-63
    • (1987) J Neurol , vol.234 , pp. 62-63
    • Goda, S.1    Hamada, T.2    Ishimoto, S.3    Kobayashi, T.4    Goto, I.5    Kuroiwa, Y.6
  • 59
    • 33745739157 scopus 로고    scopus 로고
    • Circulating cholesterol levels, apolipoprotein e genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: Results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial
    • DOI 10.1111/j.1600-0404.2006.00690.x
    • Browne P. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's disease cholesterol-lowering treatment (ADCLT) trial. Acta Neurol Scand Suppl 2006;185:3-7 (Pubitemid 44015218)
    • (2006) Acta Neurologica Scandinavica , vol.114 , Issue.SUPPL. 185 , pp. 3-7
    • Sparks, D.L.1    Connor, D.J.2    Sabbagh, M.N.3    Petersen, R.B.4    Lopez, J.5    Browne, P.6
  • 60
    • 0346872978 scopus 로고    scopus 로고
    • Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials
    • Vrecer M, Turk S, Drinovec J, Mrhar A. Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke: meta-analysis of randomized trials. Int J Clin Pharmacol Ther 2003;41:567-577 (Pubitemid 37527563)
    • (2003) International Journal of Clinical Pharmacology and Therapeutics , vol.41 , Issue.12 , pp. 567-577
    • Vrecer, M.1    Turk, S.2    Drinovec, J.3    Mrhar, A.4
  • 61
    • 0037031061 scopus 로고    scopus 로고
    • MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebo-controlled trial
    • DOI 10.1016/S0140-6736(02)09327-3
    • Collins R, Armitage J, Parish S, Sleight P, Peto R. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebocontrolled trial. Lancet 2002;360:7-22 (Pubitemid 34756487)
    • (2002) Lancet , vol.360 , Issue.9326 , pp. 7-22
    • Collins, R.1    Armitage, J.2    Parish, S.3    Sleight, P.4    Peto, R.5
  • 62
    • 0033153235 scopus 로고    scopus 로고
    • Compliance with Fluvastatin Treatment Characterization of the Noncompliant Population within a Population of 3845 Patients with Hyperlipidemia
    • DOI 10.1016/S0895-4356(99)00019-0, PII S0895435699000190
    • Bruckert E, Simonetta C, Giral P, for the CREOLE Study Team. Compliance with fluvastatin treatment characterization of the noncompliant population within a population of 3845 patients with hyperlipidemia. J Clin Epidemiol 1999;52: 589-594 (Pubitemid 29284819)
    • (1999) Journal of Clinical Epidemiology , vol.52 , Issue.6 , pp. 589-594
    • Bruckert, E.1    Simonetta, C.2
  • 64
    • 67650806451 scopus 로고    scopus 로고
    • Do low dose statins affect cognition? Results of the UCSD statin study
    • abstract
    • Golomb BA, Dimsdale JE, White HL, Criqui MH. Do low dose statins affect cognition? Results of the UCSD statin study [abstract]. Circulation 2006;114(18 suppl):II-289
    • (2006) Circulation , vol.114 , Issue.18 SUPPL.
    • Golomb, B.A.1    Dimsdale, J.E.2    White, H.L.3    Criqui, M.H.4
  • 69
    • 0033772113 scopus 로고    scopus 로고
    • Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme a reductase inhibitors
    • Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3- hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000;57:1439-1443 (Pubitemid 30769120)
    • (2000) Archives of Neurology , vol.57 , Issue.10 , pp. 1439-1443
    • Wolozin, B.1    Kellman, W.2    Ruosseau, P.3    Celesia, G.G.4    Siegel, G.5
  • 72
    • 46049109962 scopus 로고    scopus 로고
    • Re: Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease
    • [correspondence]. author reply 2350
    • Golomb BA, Evans MA. Re: statin therapy is associated with reduced neuropathologic changes of Alzheimer disease [correspondence]. Neurology 2008;70:2349; author reply 2350
    • (2008) Neurology , vol.70 , pp. 2349
    • Golomb, B.A.1    Evans, M.A.2
  • 73
  • 76
    • 36749076342 scopus 로고    scopus 로고
    • Statins and peripheral neuropathy
    • Adverse Drug Reactions Advisory Committee (ADRAC). Available from
    • Adverse Drug Reactions Advisory Committee (ADRAC). Statins and peripheral neuropathy. Aust Adverse Drug React Bull 2005;24(2):6. Available from http://www.tga. health.gov.au/ adr/aadrb/aadr0504.htm
    • (2005) Aust Adverse Drug React Bull , vol.24 , Issue.2 , pp. 6
  • 77
    • 4344658296 scopus 로고    scopus 로고
    • Statin-associated peripheral neuropathy: Review of the Literature
    • DOI 10.1592/phco.24.13.1194.38084
    • Chong PH, Boskovich A, Stevkovic N, Bartt RE. Statinassociated peripheral neuropathy: review of the literature. Pharmacotherapy 2004;24:1194-1203 (Pubitemid 39128843)
    • (2004) Pharmacotherapy , vol.24 , Issue.9 , pp. 1194-1203
    • Chong, P.H.1    Boskovich, A.2    Stevkovic, N.3    Bartt, R.E.4
  • 80
    • 33750032561 scopus 로고    scopus 로고
    • Volume reduction of the entorhinal cortex in subjective memory impairment
    • Jessen F, Feyen L, Freymann K, et al. Volume reduction of the entorhinal cortex in subjective memory impairment. Neurobiol Aging 2006;27:1751-1756
    • (2006) Neurobiol Aging , vol.27 , pp. 1751-1756
    • Jessen, F.1    Feyen, L.2    Freymann, K.3
  • 82
    • 0032927814 scopus 로고    scopus 로고
    • Association between memory complaints and incident Alzheimer's disease in elderly people with normal baseline cognition
    • Geerlings MI, Jonker C, Bouter LM, Ader HJ, Schmand B. Association between memory complaints and incident Alzheimer's disease in elderly people with normal baseline cognition. Am J Psychiatry 1999;156:531-537 (Pubitemid 29162972)
    • (1999) American Journal of Psychiatry , vol.156 , Issue.4 , pp. 531-537
    • Geerlings, M.I.1    Jonker, C.2    Bouter, L.M.3    Ader, H.J.4    Schmand, B.5
  • 83
    • 17444396712 scopus 로고    scopus 로고
    • Cognitive deficits 3 to 6 years before dementia onset in a population sample: The Honolulu-Asia Aging Study
    • DOI 10.1111/j.1532-5415.2005.53163.x
    • Jorm AF, Masaki KH, Petrovitch H, Ross GW, White LR. Cognitive deficits 3 to 6 years before dementia onset in a population sample: the Honolulu-Asia aging study. J Am Geriatr Soc 2005;53:452-455 (Pubitemid 41623524)
    • (2005) Journal of the American Geriatrics Society , vol.53 , Issue.3 , pp. 452-455
    • Jorm, A.F.1    Masaki, K.H.2    Petrovitch, H.3    Ross, G.W.4    White, L.R.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.